Krystal Biotech, Inc.
KRYS Nasdaq
SEC CIK 1711279
Follow Krystal Biotech
Weekly email: filings, results
Revenue, last quarter
$127.3M
+30.2% vs same quarter last year
Net income
$63.1M
−20.5% vs same quarter last year
EPS, diluted
$2.05
−22.9% vs same quarter last year
Operating cash flow
$91.2M
+130.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $389.1M | $204.8M |
| FY24 | $290.5M | $89.2M |
| FY23 | $50.7M | $10.9M |
| FY22 | $0 | −$140M |
| FY21 | $0 | −$69.6M |
| FY20 | - | −$32.2M |
| FY19 | - | −$19.1M |
| FY18 | - | −$10.9M |
| FY17 | - | −$7.9M |
| FY16 | - | −$1.2M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 41.5% | 52.6% |
| FY24 | 22.6% | 30.7% |
| FY23 | −216.2% | 21.6% |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $188.9M |
| FY24 | $119.2M |
| FY23 | −$100.6M |
| FY22 | −$153.5M |
| FY21 | −$116.3M |
| FY20 | −$40.9M |
| FY19 | −$25.1M |
| FY18 | −$11.7M |
| FY17 | −$4.1M |
| FY16 | −$1.3M |
- Krystal Biotech
- Healthcare median
Show the numbers
| Year | Krystal Biotech | Healthcare median |
|---|---|---|
| FY25 | 52.6% | −30.6% |
| FY24 | 30.7% | −47% |
| FY23 | 21.6% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |